NCT07538388 Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
| NCT ID | NCT07538388 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Postinduction Hypotension |
| Study Type | INTERVENTIONAL |
| Enrollment | 446 participants |
| Start Date | 2026-05-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 446 participants in total. It began in 2026-05-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients.
Eligibility Criteria
Inclusion Criteria: We will include consenting patients ≥45 years scheduled for elective major non-cardiac surgery under general anesthesia with planned continuous intra-arterial blood pressure monitoring with a radial arterial catheter and with at least two of the following risk criteria for developing acute kidney injury: * Age ≥65 years * ASA physical status III or IV * Chronic arterial hypertension * Diabetes mellitus requiring medication * Intra-abdominal surgery * Preoperative renal insufficiency (serum creatinine ≥1.2 mg/dL) Exclusion Criteria: * Pregnancy * Cardiac arrhythmia * History of intracranial hemorrhage or intracranial aneurysm * Clinical indication for continuous norepinephrine infusion during induction of general anesthesia (e.g., severe aortic valve stenosis, coronary artery disease, or heart failure) * Patients who are unable to understand, read, and provide informed consent in German
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07538388 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Postinduction Hypotension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07538388 currently recruiting?
Yes, NCT07538388 is actively recruiting participants. Contact the research team at kr.thomsen@uke.de for enrollment information.
Where is the NCT07538388 trial being conducted?
This trial is being conducted at Düsseldorf, Germany, Giessen, Germany, Hamburg, Germany, München, Germany.
Who is sponsoring the NCT07538388 clinical trial?
NCT07538388 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 446 participants.